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Summary. Background: Changes in the numbers of 
PYY- and enteroglucagon-immunoreactive cells in colon 
of animal models of human diabetes have been reported. 
As these peptides CO-localize in the same cells it is 
possible that the observed changes are a result of 
changes in CO-localization. Methods: Animal models of 
human type 1 and type 2 diabetes, namely the non-obese 
diabetic (NOD) mouse and the obese (oblob) mouse, 
were studied. As controls for the NOD mice, BALBIcJ 
mice were used and for oblob mice, homozygous lean 
(+l+) mice were used. Tissue samples from colon were 
double-immunostained for PYY and enteroglucagon 
according to the indirect immunofluorescence method. 
Results: CO-localization of enteroglucagon and PYY was 
found in colonic endocrine cel ls  in all groups 
investigated. Compared with controls, pre-diabetic NOD 
mice showed a decreased proportion of entero- 
glucagon1PYY CO-localization. There was no difference 
in diabetic NOD mice or diabetic oblob mice when 
compared with controls. Conclusions: Whereas the 
number of cells containing solely enteroglucagon and 
solely PYY increases in pre-diabetic NOD mice, 
production of enteroglucagon in PYY-immunoreactive 
cells decreases. Although the numbers of PYY and 
enteroglucagon cells have been reported to be changed 
in both diabetic NOD mice and in obese mice, the 
balance between CO-expressing and mono-expressing 
cells seems to be preserved. 
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Introduction 
Peptide YY (PYY) inhibits the secretion of fluid and 
electrolytes from the intestine (Mannon and Taylor, 
1994; Sundler et al., 1989). It is also a potent mediator of 
ileal brake, inhibits gastric emptying and delays 
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intestinal transit (Mannon and Taylor, 1994; Sundler et 
al., 1989). Enteroglucagon is a potent incretin substance, 
i.e. i t  st imulates the release of insulin from the 
pancreatic islets (Walsh, 1994). In man, as in other 
mammals, numerous enteroglucagon- and peptide YY 
(PYY)-containing endocrine cells are present in the 
mucosa of the terminal ileum and colon (El-Salhy et al., 
1983a,b; El-Salhy and Grimelius, 1983; El-Salhy and 
Lundqvist, 1984; Sundler et al., 1989; Walsh, 1994). 
PYY and enteroglucagon CO-localize in intestinal L-cells 
of rat, pig and man (Mannon and Taylor, 1994). PYY 
also occurs in another cell type, namely intestinal H- 
cells (El-Salhy et al., 1983a; Mannon and Taylor, 1994). 
Since PYY and enteroglucagon are synthetic products of 
distinct precursors, it has been suggested that the L-cell 
expresses two different genes (Mannon and Taylor, 
1994). 
Patients with diabetes mellitus often suffer from 
disturbed motility in the gut (Feldman and Schiller, 
1983; Valdovinos et al., 1993; Locke, 1995), and it may 
be that these peptides are involved in the pathogenesis of 
this disturbance. In support of this assumption, recent 
findings in an animal model of human type 1 diabetes, 
namely the non-obese diabetic (NOD) mouse, showed an 
increase in the number of enteroglucagon-immuno- 
reactive (IR) cells in pre-diabetic NOD mice and a 
decrease in the number of PYY-IR cells in diabetic 
animals (SplngCus and El-Salhy, 1998). Furthermore, 
both PYY- and enteroglucagon-IR cells have been found 
to decrease in number in the obese diabetic mouse, an 
animal model of human type 2 diabetes (SpAngCus and 
El-Salhy, 1999). It is not clear, however, whether the 
change in the numbers of PYY- and enteroglucagon-IR 
cells in these animal models is a real change, or is 
caused by the production of only one peptide instead of 
two in these cells. 
The present study was undertaken to establish 
whether the diabetic state affects the CO-localization of 
PYY and enteroglucagon. For this purpose, the co- 
localization of PYY and enteroglucagon was 
investigated in the colon of animal models of human 
type 1 (Makino et al., 1980; Kolb, 1987; Tochino, 1987) 
and type 2 (Herberg and Coleman, 1977; Lord and 
Atkins, 1985) diabetes; namely the NOD and oblob 
diabetic mice. 




